Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsCaroline Litchfield - Executive ...
Crain's New York

Merck to slash $3B in costs as patent cliff for hallmark cancer med nears

Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will cut administrative, ...
Business Wire

Merck to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio

HUB internationally recognized pioneer in organoid development Acquisition expands Merck’s 2D and 3D cell culture portfolio Organoids part of fastest growing cell culture segment; hold potential to ...
ZAWYA

Merck introduces educational symptom checker to support earlier detection of colorectal cancer across the Gulf

Merck, a leading science and technology company, is reinforcing the importance of early detection by introducing an online ...
Hosted on MSN

Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?

Merck MRK is a prominent pharmaceutical company with a strong position in oncology. Its blockbuster drug, Keytruda, and new products have been driving sales. Animal health is also contributing to ...
Nasdaq

Does This Move Make Merck Stock a Buy?

Merck (NYSE: MRK), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its famous ...